Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information.
Similar Posts
MHRA appoints first Chief Medical and Scientific Officer
Professor Jacob George has been appointed as the first Chief Medical and Scientific Officer for the Medicines and Healthcare products Regulatory Agency (MHRA).
New review highlights untapped potential of the vaginal microbiome in women’s health
The microscopic bacteria living in women’s bodies could be a powerful tool for personalised, non-invasive treatment and earlier diagnosis.
MHRA approves Siiltibcy as a diagnostic aid for Mycobacterium tuberculosis infection, including disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Siiltibcy
Guidance: Field safety notice (FSN): what it is and why it’s important
A flyer to circulate to customers alongside a field safety notice covering what it is and why it’s important to take action.
Class 4 Medicines Defect Notification: Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals NV, EL(25)A/37
Jubilant Pharmaceuticals NV has informed the MHRA that the Patient Information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.
Form: Medicines marketing authorisation: change of ownership application
Use this form to transfer a product licence, also known as a marketing authorisation, to a different owner.